Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095391
Filing Date
2024-08-12
Accepted
2024-08-12 16:03:23
Documents
72
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q alxo-20240630.htm   iXBRL 10-Q 2327408
2 EX-31.1 alxo-ex31_1.htm EX-31.1 16799
3 EX-31.2 alxo-ex31_2.htm EX-31.2 17001
4 EX-32.1 alxo-ex32_1.htm EX-32.1 9486
5 EX-32.2 alxo-ex32_2.htm EX-32.2 9500
  Complete submission text file 0000950170-24-095391.txt   8411622

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20240630.xsd EX-101.SCH 1028329
74 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20240630_htm.xml XML 1418732
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39386 | Film No.: 241196673
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)